ArticleFrontiers in immunology2026
Case Report: Nasal swelling and ulceration as a unique immune-related cutaneous adverse event of atezolizumab in small cell lung cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article reports a rare immune-related cutaneous adverse event (ircAE) manifesting as nasal swelling and ulceration in a patient with small cell lung cancer (SCLC) after treatment with atezolizumab. A patient with extensive-stage SCLC developed symptoms of nasal swelling and ulceration during treatment with atezolizumab combined with anlotinib. Based on clinical test results, we ruled out infections and autoimmune diseases. Histopathological analysis of the lesion biopsy excluded metastatic carcinoma. According to the patient's medication history, we considered that the nasal swelling and ulceration were extremely rare ircAEs caused by atezolizumab. After we discontinued immunotherapy and administered glucocorticoids, the patient's nasal skin symptoms improved significantly. We searched multiple medical databases such as PubMed, but did not find similar reports.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.